Successful Progressive Challenge after a Cutaneous Reaction to Imatinib Mesylate (Gleevec): A Case Report and Review of the Literature

Authors: Park, Miguel A.; Volcheck, Gerald W.; Guarderas, Juan C.

Source: Allergy and Asthma Proceedings, Volume 25, Number 5, September-October 2004 , pp. 345-347(3)

Publisher: OceanSide Publications, Inc

Buy & download fulltext article:

Price: $39.50 plus tax (Refund Policy)

Abstract:

The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature.

Document Type: Research article

Publication date: 2004-09-01

More about this publication?

Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
Editorial Board
Information for Authors
Submit a Paper
Information for Advertisers
Reprint Requests
ingentaconnect is not responsible for the content or availability of external websites